Tyler Jacks
Direttore/Membro del Consiglio presso THERMO FISHER SCIENTIFIC INC.
Patrimonio netto: 9 M $ in data 30/11/2024
Profilo
Tyler E.
Jacks is the founder of T2 Biosystems, Inc. (founded in 2006) and Dragonfly Therapeutics, Inc. (founded in 2016).
He currently holds positions as an Independent Director at Amgen, Inc. (since 2012), Director at Thermo Fisher Scientific, Inc. (since 2009), President & Director at Commonwealth Cancer Consortium, Inc. (since 2021), and Professor at Massachusetts Institute of Technology (since 2007).
Dr. Jacks previously served as Chairman at the National Cancer Institute and as Director at the David H.
Koch Institute for Integrative Cancer Research (from 2007 to 2021).
He received his undergraduate degree from Harvard University in 1983 and his doctorate degree from The University of California, San Francisco in 1988.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
AMGEN INC.
0.00% | 31/05/2024 | 16 005 ( 0.00% ) | 5 M $ | 30/11/2024 |
22/05/2024 | 8 398 ( 0.00% ) | 4 M $ | 30/11/2024 |
Ultime notizie su Tyler Jacks
Posizioni attive di Tyler Jacks
Società | Posizione | Inizio |
---|---|---|
THERMO FISHER SCIENTIFIC INC. | Direttore/Membro del Consiglio | 26/05/2009 |
AMGEN INC. | Direttore/Membro del Consiglio | 01/01/2012 |
Massachusetts Institute of Technology | Corporate Officer/Principal | 01/01/2007 |
Commonwealth Cancer Consortium, Inc.
Commonwealth Cancer Consortium, Inc. Commonwealth Cancer Consortium, Inc., also known as Break Through Cancer, is a foundation that supports teams from leading scientific research hospitals and centers focused on cancer research. The foundation aims to empower outstanding researchers and physicians to intercept and find cures for the deadliest cancers by stimulating radical collaboration. Break Through Cancer collaborates with five top cancer research centers in the world. The organization is committed to reducing barriers to cross-institutional collaboration and expects radical collaboration from all researchers, physicians, and other partners. The company is based in Cambridge, MA. | Presidente | 01/02/2021 |
Precedenti posizioni note di Tyler Jacks
Società | Posizione | Fine |
---|---|---|
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | 01/01/2021 |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Presidente | 01/01/2016 |
T2 BIOSYSTEMS, INC. | Fondatore | 01/01/2013 |
Dragonfly Therapeutics, Inc.
Dragonfly Therapeutics, Inc. BiotechnologyHealth Technology Dragonfly Therapeutics, Inc. develops therapy to stimulate immune responses against cancer. The company was founded by Tyler Jacks, Bill Haney and David Raulet in 2015 and is headquartered in Waltham, MA. | Fondatore | - |
Formazione di Tyler Jacks
Harvard University | Undergraduate Degree |
The University of California, San Francisco | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
T2 BIOSYSTEMS, INC. | Health Technology |
THERMO FISHER SCIENTIFIC INC. | Health Technology |
AMGEN INC. | Health Technology |
Aziende private | 4 |
---|---|
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | Commercial Services |
Dragonfly Therapeutics, Inc.
Dragonfly Therapeutics, Inc. BiotechnologyHealth Technology Dragonfly Therapeutics, Inc. develops therapy to stimulate immune responses against cancer. The company was founded by Tyler Jacks, Bill Haney and David Raulet in 2015 and is headquartered in Waltham, MA. | Health Technology |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
Commonwealth Cancer Consortium, Inc.
Commonwealth Cancer Consortium, Inc. Commonwealth Cancer Consortium, Inc., also known as Break Through Cancer, is a foundation that supports teams from leading scientific research hospitals and centers focused on cancer research. The foundation aims to empower outstanding researchers and physicians to intercept and find cures for the deadliest cancers by stimulating radical collaboration. Break Through Cancer collaborates with five top cancer research centers in the world. The organization is committed to reducing barriers to cross-institutional collaboration and expects radical collaboration from all researchers, physicians, and other partners. The company is based in Cambridge, MA. |
- Borsa valori
- Insiders
- Tyler Jacks